Nanolive’s cutting edge label-free microscope devices and state-of-the-art digital analytical solutions provide researchers and scientists working in the biopharmaceutical industry and laboratories with all the tools required to accelerate innovation in growth industries such as drug discovery and cell therapy.
Being able to screen thousands of living cells in 3D, without damaging them promises to radically advance how scientists study living cells. Moreover, the quantitative analytical suite the Vaud-based scale-up offers is a complete game-changer.
Combining sub-cellular resolution with unique AI-assisted digital assays provide researchers and scientists a unique opportunity to study complex cell-drug perturbation dynamics and cell-cell interactions (e.g., T cell and target cell interactions), quantitatively, an approach that will revolutionize the cell-based assay phase of the drug discovery workflow.
Nanolive’s USD 20 million Series C-1 equity financing round was led by a US-based and NASDAQ listed life science investor, and Taiwania Capital, a leading life science venture capital company based in Taiwan. The round of investment was also supported by existing investors, including Swisscom Ventures, along with other partners.
Transforming the discovery and development of therapteutics
“Life Sciences are undergoing a fundamental transformation, and Nanolive is at the heart of it,” said Dr. Yann Cotte, CEO and Co-Founder of Nanolive. “We are honored to receive an investment from such an impressive group of investors who are excited to support us in our goal to transform the discovery and development of therapeutics. With this fundraising, we believe Nanolive is well positioned to drive significant growth of our Digital Assay solutions and is at the leading edge of this global bioeconomy gold rush. We are selling the best picks and shovels for live cell solutions.”
